National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C

This study measures changes in patient and prescriber characteristics for direct-acting antivirals to treat hepatitis C virus infection from 2013 to 2025 in the US.

Corresponding Author: Sanjay Kishore, MD, University of Virginia School of Medicine, 1215 Lee St, Charlottesville, VA 22903 (sanjay.kishore@uvahealth.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.